Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tirofiban + oxiracetam is a combination of two pharmaceutical agents, each with distinct mechanisms of action. Tirofiban is a non-peptide antagonist of the platelet glycoprotein IIb/IIIa receptor, used primarily as an antiplatelet agent to inhibit platelet aggregation and reduce thrombotic cardiovascular events in acute coronary syndromes. Oxiracetam is a nootropic compound from the racetam family, known for its cognitive-enhancing and neuroprotective effects; it modulates AMPA receptors in the brain to improve memory and cognition. The combination has been investigated in clinical studies for potential synergistic effects, particularly in acute progressive cerebral infarction, but there are no widely approved indications for this specific combination[2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tirofiban + oxiracetam.